November 18, 2014

111914TheCenterSecondone640

Texas Children’s Health Plan opened its second location of The Center for Children and Women on November 11. The approximately 65,000-square-foot facility, which is located at 9700 Bissonnet Street in the Southwest Corporate Center, provides comprehensive medical care for Texas Children’s Health Plan members in the Southwest area of Houston.

Through a partnership with Baylor College of Medicine, the patient- and family-centered medical home includes pediatricians, advanced nurse practitioners, OB/GYNs, certified nurse midwives, optometrists, imaging specialists, speech therapists, a laboratory, and an onsite pharmacy. There are also plans to add dentistry services. Having all these services under one roof makes it possible for members to have their medical needs met on the same day and in the same location.

“Texas Children’s Health Plan is very proud to expand The Center for Children and Women to another location in Houston,” said Christopher Born, Texas Children’s Health Plan president. “The Center for Children and Women model has exceeded our expectations at our Greenspoint location and we look forward to the same success at the Southwest location.”

The new facility is the second Texas Children’s Health Plan – The Center for Children and Women to open in the past year and a half. The first facility opened in the Greenspoint area in August of 2013 and has made a great impact on the surrounding community. Within its first year of operation, The Center for Children and Women in Greenspoint completed more than 27,000 appointments, delivered more than 260 births, and hosted breastfeeding, car seat safety, and new parent classes to help educate the community. The facility also received National Committee for Quality Assurance recognition and was selected by Texas Health and Human Services for a national pregnancy medical home pilot program.

“Our goal is to ensure that Texas Children’s Health Plan members receive the same level of care as those with commercial health insurance,” stated Tangula Taylor, director of operations at The Center for Children and Women. “We are very proud of what we have accomplished in the time that the Greenspoint location has been open and we are uniquely positioned to serve the Medicaid and CHIP populations in Southwest Houston with the same commitment.”

111914NEC640

What is supposed to be a joyous occasion – the birth of your baby – suddenly gives way to anxiety. While you know the next few months are critical to your premature infant’s survival, you never expect to hear this dreaded diagnosis: “Your baby has necrotizing enterocolitis.”

Texas Children’s Neonatologist Dr. Amy Hair is on a crusade to protect fragile and premature infants from necrotizing enterocolitis (NEC), a life-threatening neonatal condition that causes inflammation and death of intestinal tissue. In the worst cases of NEC, perforations develop in the intestine which may require portions of the intestine to be surgically removed.

Since the internal organs of premature infants are not fully developed, they are more susceptible to NEC, which claims the lives of 500 premature infants each year in the United States. Jennifer Canvasser, a mother whose infant son died of NEC, knows this reality all too well. “My son Micah was critically ill when I first heard about NEC. In a matter of hours, Micah went from being a beautiful five-pound baby to being critically ill and intubated with cords, wires and tubes on each of his extremities.”

Micah’s tragic outcome and one from Hair’s earlier years in residency – she treated a baby who died of NEC – motivated Hair to protect premature infants from this deadly disease by encouraging nursing mothers to donate the lifesaving gift of breast milk.

“Breast milk donors are lifesavers,” said Hair. “Unlike formula derived from cow protein – which is known to increase the risk of NEC – breast milk contains antibodies and anti-inflammatory factors that protect babies against NEC and a host of bacterial infections.”

Hair says the most effective way to reduce the rate of NEC is by feeding infants a human milk diet, which supports the guidelines issued by the American Academy of Pediatrics. This diet consists of mother’s own milk, pasteurized donor breast milk and protein fortifiers that add calories and nutrients to human milk to help critically-ill infants grow and thrive.

Since Texas Children’s implemented its exclusive human milk feeding protocol in 2009, NEC rates in our NICU have dropped significantly from the national average of 10 -12 percent to 2 percent. Hair attributes this remarkable decline to the generous mothers who donate their breast milk to Texas Children’s Mother’s Milk Bank, many of whom are Texas Children’s employees.

“Every ounce of donor breast milk improves neonatal outcomes in our NICU,” said Hair. “If more mothers donate their excess supply to our Milk Bank, we can ensure our tiniest, most vulnerable patients receive a constant supply of nourishment and protection to stay healthy.”

As the associate medical director of neonatal nutrition at Texas Children’s, Hair has devoted her entire research to neonatal nutrition and delivers numerous presentations each year touting the lifesaving benefits of human milk at pediatric research conferences wordwide.

She also serves as a scientific advisor to the NEC Society, a non-profit organization that was established by Canvasser to honor her son, Micah, increase awareness about the lifesaving power of human milk, and encourage more mothers to donate their breast milk to protect babies from NEC.

Dr. Hair’s call-to-action is simple: Donate breast milk and save a baby’s life.

Click Texas Children’s Mother’s Milk Bank to learn more about our donor breast milk program.

111914PediatricPilotAwardsinside640

Dr. Susan Blaney, executive vice chair of Research in the Department of Pediatrics, recently announced the winners of the 2014 Pediatric Pilot Awards Research Grant Program. Twelve research applications were chosen by review committee members to receive grant funding in the amount of up to $50,000 for their projects.

The purpose of the Pediatric Pilot Awards Research Grant Program is to provide initial start-up “seed funding” for research projects. This grant program provides opportunities for new or less established researchers as well as experienced researchers who desire to expand their area of research. The grant projects are awarded based upon their scientific merit and the potential to generate the initial data necessary for a successful grant application submission to the NIH or other external, peer-reviewed funding mechanisms.

The pilot award program is a collaborative effort between Texas Children’s Hospital and its academic partner, Baylor College of Medicine.

Congratulations to the following 2014 pilot grant awardees. Click on the name below to learn more about the research project being funded.

Ronald Bernardi, M.D., Ph.D.
Assistant Professor, Pediatrics – Hematology/Oncology
Combinatorial tyrosine kinase inhibition as a novel therapeutic strategy in PTPN12-deficient pediatric cancers

Jennifer Foster, M.D.
Instructor, Pediatrics – Hematology/Oncology
Pre-clinical evaluation of ML4924, a novel NEDD-8 activating enzyme inhibitor in pediatric malignancies

Andras Heczey, M.D.
Assistant Professor, Pediatrics – Hematology/Oncology
Glypican-3 specific T cells to cure pediatric liver disease

Marisa Hilliard, Ph.D.
Assistant Professor, Pediatrics – Psychology
Promoting resilience in youth with type 1 diabetes: Pilot of a strengths-based family intervention to improve diabetes outcomes

Jimmy Holder, M.D.
Assistant Professor, Pediatrics – Neurology
Identifying post-translational regulators of SHANK3 – toward developing targeted therapeutics for neuropsychiatric disorders in children

Dongfang Liu, Ph.D.
Assistant Professor, Pediatrics – Immunology, Allergy and Rheumatology
Super-resolution imaging of HIV-specific CTL immunological synapse

Silke Paust, Ph.D.
Assistant Professor, Pediatrics – Immunology, Allergy and Rheumatology
Pollen grains as trojan horses for child-friendly oral vaccination

Elaine Seto, M.D., Ph.D.
Assistant Professor, Pediatrics – Neurology and Development Neuroscience
Investigating the role of dopamine in neurocognitive function

Amy Sims, M.D.
Assistant Professor, Pediatrics – Cardiology
Clinical-Officer led screening for rheumatic heart disease in Malawi, Africa

Bernard Suter, M.D.
Assistant Professor, Pediatrics – Neurology and Development Neuroscience
In vivo analysis of motor cortex function in the MECP2 duplication mouse

Scott Wenderfer,M.D., Ph.D.
Assistant Professor, Pediatrics – Renal
Novel Auto-antibody Markers of Lupus Nephritis

Janice Zawaski, Ph.D.
Assistant Professor, Pediatrics – Hematology/Oncology
The role of bone marrow in glioma radiotherapy response

 

———————————————————————————————————————————-

 

Ronald Bernardi, M.D., Ph.D.
Assistant Professor – Hematology/Oncology
Combinatorial tyrosine kinase inhibition as a novel therapeutic strategy in PTPN12-deficient pediatric cancers

Some cancers are driven primarily by increased activity of a single proliferation signal. Frequently, this abnormal stimulatory signal comes from an overactive tyrosine kinase, a class of enzymes that regulate cellular proliferation by adding phosphate groups to substrate proteins.

In this setting, specific tyrosine kinase inhibitors can limit the progression of the disease and even cause tumor regression. The development of such agents has improved outcomes dramatically for some cancers. However, for the vast majority of pediatric malignancies, the situation is not so straightforward. Thus, current options for therapy for many pediatric cancer patients remain limited in that they either have serious side effects or are ineffective.

We propose an approach that may broaden the use of tyrosine kinase inhibitors. Tyrosine phosphatases are a class of proteins that normally function to counteract the activity of tyrosine kinases. As tyrosine phosphatases typically have several substrates, loss of a tyrosine phosphatase may aberrantly activate multiple tyrosine kinases, which can act in concert to promote tumor progression.

We previously identified PTPN12 as a tyrosine phosphatase that is frequently deficient in breast cancer, leading to the activation of a number of tyrosine kinases. Combinatorial inhibition of these activated tyrosine kinases reduced proliferation of PTN12-deficient models that are resistant to single agents. We also have preliminary evidence that diminished PTPN12 expression correlates with poor prognosis in pediatric cancers. In this pilot project, we aim to more thoroughly assess the spectrum of loss of PTPN12 in pediatric cancers and to assess the functional role of PTPN12 and identify the tyrosine kinases that it regulates in this setting. Further, we plan to test the combined inhibition of PTPN12 regulated tyrosine kinases for the ability to inhibit the growth of pediatric cancers that have diminished PTPN12.

Our results will be critical for designing clinical trials of drug combinations that are tailored to the genetic alterations and susceptibilities of each individual tumor.

Jennifer Foster, M.D.
Instructor – Hematology/Oncology
Pre-clinical evaluation of ML4924, a novel NEDD-8 activating enzyme inhibitor in pediatric malignancies

Neuroblastoma is a devastating form of cancer that develops from immature nerve cells. Only half of children diagnosed with high-risk neuroblastoma survive beyond childhood. New treatments are needed to improve their survival.

In our proposed study, we will examine a novel chemotherapeutic agent, MLN4924. MLN4924 kills neuroblastoma cells differently than standard chemotherapy. The traditional way to kill neuroblastoma tumor cells has been to attack their DNA. However, in this proposal, we will test another mechanism which involves killing neuroblastoma cells by preventing protein breakdown. Blocking protein breakdown with a new drug, MLN4924, will result in “proteotoxic stress” that can kill the cancer cells following standard chemotherapy, improving our ability to kill tumor cells.

MLN4924 is currently undergoing testing in adults with various forms of cancer and has yielded promising results. Adults with relapsed or difficult to cure cancer treated with MLN4924 experience improved survival with minimal side effects. Our goal is to improve clinical outcomes in neuroblastoma by adding MLN4924 to standard chemotherapy regimens. Our preliminary data shows that MLN4924 is effective at killing neuroblastoma cells.

This research will provide the pre-clinical data necessary to successfully incorporate MLN4924 into pediatric clinical trials and is being conducted in conjunction with a proposed Phase 1 clinical trial run by the National Cancer Institute (NCI)-sponsored Children’s Oncology Group (COG). In this proposal we will determine 1) with what chemotherapies MLN4924 works best in conjunction to kill neuroblastoma cells and 2) how neuroblastoma cells are dying after treatment with MLN4924. This information is crucial in optimally designing future clinical trials for patients with neuroblastoma which will combine MLN4924 with standard anti-cancer agents. The addition of novel anti-cancer drugs, such as MLN4924, to the treatment regimen of children with neuroblastoma is crucial in improving their survival.

Andras Heczey, M.D.
Assistant Professor – Hematology/Oncology
Glypican-3 specific T cells to cure pediatric liver disease

Hepatoblastoma and hepatocellular carcinoma are the most common forms of liver cancer in children. Despite severe side effects, current medical therapies have limited effectiveness in patients whose tumors cannot be surgically removed completely.

In our study, we propose to collect and genetically modify special immune cells from the blood to destroy liver cancer cells in the laboratory. Our long-term goal is to develop a new immunotherapy method by genetically engineering the patient’s own immune system to eliminate liver cancer without the toxicity of current therapies.

Marisa Hilliard, Ph.D.
Assistant Professor of Pediatrics – Psychology
Promoting resilience in youth with type 1 diabetes: Pilot of a strengths-based family intervention to improve diabetes outcomes

Type 1 diabetes is a common chronic condition characterized by the body’s inability to produce insulin due to the autoimmune destruction of the beta cells in the pancreas.

The daily management requirements of type 1 diabetes are complex and demanding. Adolescence is a particularly difficult period as teens begin to assume responsibility for their own diabetes management and worsening glycemic control is common during this time.

Complex issues that make diabetes even more challenging to manage for adolescents include family disagreements about diabetes, depression, and “diabetes burnout.” Family factors that help teens and families manage diabetes more easily include being good problem-solvers, ongoing parent support, and coping with diabetes challenges in an optimistic way.

Psychologists and physicians have developed intervention programs to promote good diabetes outcomes and most have focused on minimizing the impact of diabetes challenges. However, there are fewer programs designed to promote good diabetes outcomes by building on teens’ and families’ existing strengths.

Thus, the purpose of this study is to pilot test an intervention program that will recognize specific actions teens with diabetes and their families do well for their diabetes management (such as talking to friends about diabetes and asking parents for help when needed) in order to strengthen those positive diabetes behaviors.

As part of the intervention, teens and their parents will complete a web-survey before attending two routine visits with their diabetes care provider. The web-survey will include a questionnaire about positive diabetes behaviors and one about how often the teen and family complete various diabetes management tasks (such as checking blood glucose values or giving insulin). At the diabetes clinic visits, the diabetes care provider will receive a print-out of the family’s “Diabetes Strengths Profile” and will be trained to talk with the teen and family about their strengths and successes with diabetes management during the clinical encounter, rather than focusing on what is not going well.

We hope this strengths-based family approach will help patients and families feel more satisfied with diabetes care, feel less burdened by diabetes management demands, and feel empowered to use more positive diabetes behaviors. Ultimately, we expect these improvements will translate to better quality of life and better glycemic control for adolescents with type 1 diabetes.

Jimmy Holder, M.D.
Neurology & Development Neuroscience
Identifying post-translational regulators of SHANK3 – toward developing targeted therapeutics for neuropsychiatric disorders I children

Autism is a common neurodevelopmental disorder affecting more than one in 100 children. Currently, there are no effective therapies to treat the primary symptoms of autism which include abnormal language development, socialization and restricted interests. This is largely due to our incomplete understanding of the neurobiological basis of autism.

Mutations of a gene called SHANK3 are one of the more common genetic causes of autism. In addition to the core symptoms of autism, children with mutations in SHANK3 have moderate to severe intellectual disability and often intractable epilepsy.

Through this pilot award, we will attempt to identify regulators of SHANK3 protein stability. Identifying these regulators will serve as therapeutic entry points for treating the symptoms of autism due to mutations in SHANK3 as well as potentially providing insight into the neurobiological of autism.

Dongfang Liu, Ph.D.
Assistant Professor – Immunology, Allergy and Rheumatology
Super-resolution imaging of HIV-specific CTL immunological synapse

How do some patients infected with HIV control virus levels in their blood to an undetected level without HIV medications? Why do HIV medications require a life-long commitment for patients? Can we control the virus to an undetected level without lifetime treatment?

My study will use multiple innovative, super-resolution imaging approaches in live, single cells – at the single-molecule level – to answer these critical questions and explain how one population of white blood cells fights HIV during chronic infection.

HIV is a virus that attacks the immune system in our bodies. HIV is different from other viruses because the body’s immune system never fully gets rid of it. Over time, HIV destroys the body’s ability to fight infection and disease. When that occurs, HIV infection can lead to Acquired Immune Deficiency Syndrome, or AIDS.

Cytotoxic T lymphocytes (CTLs) is one type of white blood cell that recognizes and kills HIV-infected cells in the body. However, the CTLs fail to function normally and do not prevent progression of disease in most people during chronic HIV infection. The mechanism responsible for CTLs dysfunction remains unclear.

A major gap in our current knowledge of CTLs dysfunction is the lack of understanding of the CTLs-virally infected target cell interface called immunological synapses (IS). Formation of a functional interface is required for effective CTLs responses to occur, which is essential for eradicating HIV.

HIV medications inhibit HIV but do not eradicate HIV. The virus rebounds after cessation of HIV medications. Neither eradication of the virus nor restoration of effective CTLs function can be achieved by HIV medications. Therefore, it is crucial to understand the interface between CTLs and virally infected target cells during HIV infection and to train CTLs in the body to fight HIV. Traditional biochemical and cell biological approaches do not reveal the critical spatiotemporal parameters of intracellular signal transduction cascades and dynamics of interface between CTLs and HIV-infected target cells.

My study will use high-resolution imaging at the single-molecule level to address important questions about CTLs and HIV-infected target cell’s interface. They include dynamics of interface formation (how CTLs recognize a virally infected target cell) and the critical factors determining the outcome of interface. By looking at the interface between CTLs and target cells using high-resolution imaging at the single-molecule level, we will determine the mechanism of CTLs dysfunction during chronic HIV infection. This knowledge will provide an excellent framework for designing specific protein inhibitors or antagonists to restore CTLs functions during chronic HIV infection.

Silke Paust, Ph.D.
Assistant Professor – Immunology, Allery and Rheumatology
Pollen grains as trojan horses for child-friendly oral vaccination

With the absence of a preventive or therapeutic HIV vaccine, 2.7 million new HIV infections occur annually, and over 34 million people are infected worldwide. As differences in infection levels are most pronounced among young people aged 15-24 years, a preventive HIV vaccine will need to be administered to children.

We propose to evaluate an inexpensive, child-friendly, self-administrable HIV vaccine for simple translation to the clinics. My collaborator at Texas Tech University, Dr. Gill, has developed a vaccine formulation based on pollen grains, which are cleaned to remove their allergenic compounds and refilled by vacuum with HIV protein antigens and vaccine adjuvants. Pollen-based formulations are administered orally (they are eaten), thus offering the advantages of a painless, needle-free, child-friendly, easy vaccination approach.

This pilot project is to assess the effectiveness of this novel HIV vaccine when it is administered orally to mice that have been given a human immune system. By vaccination and HIV challenge of this animal model, we can assess the quality of the human immune response upon HIV pollen vaccination and assess whether this vaccine formulation protects against HIV infection.

If successful, this project will aid in the development of an inexpensive, easy-to-transport and administer HIV vaccine that is suitable for adults and children.

Elaine Seto, M.D., Ph.D.
Assistant Professor – Neurology and Development Neuroscience
Investigating the role of dopamine in neurocognitive function

Cells of the nervous system, known as nerve cells or neurons, function through the regulated release of chemical messengers known as neurotransmitters. The human brain utilizes many different neurotransmitters to relay information from neurons to downstream cells. One neurotransmitter that has garnered significant attention is dopamine. During adulthood, misregulation of dopamine is thought to underlie the movement abnormalities seen in patients with Parkinson’s disease.

Interestingly, dopamine can be detected early in fetal brain development and misregulation in the developing brain may likely contribute to neuropsychiatric conditions such as attention deficit hyperactivity disorder (ADHD).

In a screen for modifiers of dopamine in fruit flies, we have isolated genes implicated in several neurodevelopmental conditions such as autism and intellectual disability. By altering these genes specifically in dopamine-expressing neurons, we can determine how these genes affect dopamine transmission and if these changes result in altered cognition.

My study will provide further insight into the role dopamine plays in pediatric neurocognitive disorders. This work may also lead to novel therapeutic options since medications that modulate dopamine transmission are already being utilized for other medical diagnoses.

Amy Sims, M.D.
Assistant Professor – Cardiology
Clinical-Officer Led Screening for Rheumatic Heart Disease in Malawi, Africa

While almost eradicated in the U.S., rheumatic heart disease (RHD) is the leading cause of cardiac morbidity and death among children in impoverished nations around the world, like Malawi, Africa.

RHD is a chronic heart condition caused by acute rheumatic fever which can result in severe heart valve damage. Secondary prevention consists of monthly penicillin injections for RHD patients, which prevents progression of heart valve disease. The 2012 guidelines issued by the World Heart Federation provides consensus for RHD diagnosis by echocardiography. RHD screening programs that use echocardiography to produce images of the heart’s valves and chambers are sensitive to detecting early signs of the disease. Early detection and effective secondary prevention dramatically reduces morbidity and mortality.

We conducted a study last year which was the first to establish the prevalence of RHD in Malawi. Our preliminarily findings suggest that Malawi may have one of the highest prevalences of RHD in the world. Thus, expanding the capacity to screen for RHD and enroll affected children in secondary prophylaxis programs can drastically reduce the sequaelae of this disease.

With 0.19 physicians per 1000 people in Malawi and no in-country pediatric cardiologist, it is not feasible for RHD screening to be led by physicians. Task-shifting to Clinical Officer (CO)-led RHD screening is a more sustainable option. Computer-based modules describing screening for RHD aimed at non-physicians have been developed and validated.

This pilot award project aims to train nine Malawian CO’s in echocardiographic screening for RHD. After didactic and computer-based training, each CO will accompany a pediatric cardiologist to a local Malawian school and learn to screen for RHD first hand. We expect to screen over 1000 children for RHD. Each CO will be evaluated in their ability to screen for RHD.

This study will be a step towards eradicating RHD, the leading cause of cardiac death in children worldwide.

Bernard Suter, M.D.
Assistant Professor, Neurology and Development Neuroscience
In vivo analysis of motor cortex function in the MECP2 duplication mouse

Boys born with higher levels of a specific gene called MECP2 have autism spectrum disorder. Common symptoms include severe verbal and communication problems, as well as impaired motor function Specifically, their ability to walk is perturbed and over time becomes unstable. To date, we don’t know how the control of gait is disturbed in these individuals. In the mouse model of this disease, the way the mice walk worsens over time.

My study will examine part of the mouse brain that controls movements and gait called the primary motor cortex. Our brain works by the electrical firing signals of its principal cells, the neurons. In the primary motor cortex of MeCP2-duplication mice, I look at many neurons at the same time and observe what pattern of firing they exhibit during walking and running, and compare this to the patterns observed in normal mice.
By understanding how control of gait is disrupted, we can identify methods to modify and improve gait in humans with autism spectrum disorders.

Scott Wenderfer,M.D., Ph.D.
Assistant Professor – Renal
Novel Auto-antibody Markers of Lupus Nephritis

This project will assess a novel diagnostic tool for monitoring kidney involvement in children with systemic lupus erythematosus (SLE), a chronic inflammatory condition that occurs when the body’s immune system attacks tissues and organs.

Kidney involvement in SLE often drives the therapy decisions due to its enormous impact on patient outcomes and kidney function. To date, there are no reliable non-invasive diagnostic or prognostic markers for kidney involvement in these patients. Prior research by the applicant, assessing auto-antibodies against basement membrane material, found that severe kidney disease commonly develops in children with SLE, which can change the concentration in their bloodover time, and can discriminate between subsets of SLE patients.

In this study, the ability of this novel biomarker from blood to predict kidney involvement will be tested using a collection of subjects enrolled in the Midwest Pediatric Nephrology Consortium (MWPNC), a group of over 40 pediatric centers including Baylor College of Medicine. We will correlate findings with results of the more invasive kidney biopsy test. We will also explore relationships between anti-basement membrane antibodies and current clinical measures of kidney involvement in SLE.

The results will guide the applicant’s development of future studies to examine the value of this novel diagnostic tool among pediatric lupus patients and ultimately translate these findings to clinical practice.

Janice Zawaski, Ph.D.
Assistant Professor – Hematology/Oncology
The role of bone marrow in glioma radiotherapy response

Bone marrow derived cells (BMDCs) contribute to tumor growth and are associated with a worse clinical prognosis. Upon tumor initiation, the exact pathway/mechanism by which these BMDCs are recruited, migrate, and retained in the tumor are not well understood. However, low tumor oxygenation, as a result of radiotherapy, increases the influx of BMDCs.

The goal of this research is to create and characterize a mouse brain tumor model in which the bone marrow is fluorescent (GFP+) to study the contribution of BMDCs to tumor growth. As a result of the bone marrow being fluorescent it allows us to measure the magnitude and kinetics of the influx of BMDCs into the tumor pre- and post-radiotherapy using imaging techniques (microscopy, fluorescence imaging). In addition, translational imaging (PET and MRI) techniques, similar to clinical imaging currently performed on patients, will be used to study the effect of tumor oxygenation on the recruitment of BMDCs into the tumor pre- and post-radiotherapy.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

111914Periwinklekickball640

Texas Children’s was well represented this month at the Periwinkle Foundation Kickball Classic, an event that raises money for an organization that provides healing programs and camps to children, young adults and families who are challenged by cancer and other life-threatening illnesses.

Employees from across the hospital organized 23 of the 36 teams that participated in the November 8 event at the Houston Sportsplex. Kicks R 4 Kids, the team that represented Texas Children’s Hospital’s Pediatric Radiology Department, took home the second-place title.

First place went to Lamar Squad, a team representing Lamar High School, and third place went to Kick Ballers, a team representing Bellaire High School.

More than 700 people turned out to watch the tournament, which raised $32,000 for the Periwinkle Foundation’s inaugural Kickball Classic.

The Kickball Classic involves teams of at least 10 people rallying together to raise funds while kicking to improve the lives of those affected by cancer. Each team is guaranteed three games in the round robin tournament and individuals are welcome to attend as well.

For more information about the Periwinkle Foundation, visit the organization’s website at http://periwinklefoundation.org/.

November 11, 2014

111214ebolalab640

Texas Children’s Hospital is working hard to prepare its staff and its facilities for a patient with Ebola or a similar infectious disease.

Isolation units have been designated. PPE has been purchased. Staff is being trained on how to use it. And, leaders are meeting regularly to assess the organization’s preparedness as it relates to the most current information available.

Another initiative in the works will give the hospital the capability to test for the Ebola virus onsite instead of depending solely on lab results from state and federal government laboratories.

Dr. James Versalovic, who heads up the hospital’s pathology department, said he is in the process of purchasing equipment that will allow his staff to test for Ebola and similar infectious diseases at the main campus. Being able to test for such conditions at Texas Children’s Hospital will enable medical staff to quickly determine and provide appropriate care.

Currently, lab samples from suspected Ebola patients are sent to the Texas Public Health Department in Austin and the Centers for Disease Control and Prevention in Georgia. Results are typically released within 72 hours. In the meantime, the patient is isolated and his or her symptoms are treated.

Versalovic said even with onsite diagnostic capabilities, lab samples from suspected Ebola patients still would be sent to the state and the CDC for confirmatory testing. Treatment, however, could be started sooner with the initial result in hand in hours compared with days. And, by ruling out Ebola more quickly in suspected patients, the correct diagnosis can be made more rapidly.

All onsite testing will be done at the main campus by a specialized team in a negative-pressure bio-containment laboratory. A similar unit is being planned for the west campus.

The goal is to have both labs ready and equipped to test for Ebola and other such diseases next year. The upgrades and additions will provide Texas Children’s with the best tools to diagnose and treat patients with infectious diseases, Versalovic said. The tools also will position the organization’s staff for effective patient care, optimal protection and safety.

 

Return to Ebola Response site.

 

111214openenrollment550

The enrollment period for 2015 benefits ends Friday, November 14, so you better sign up fast.

If you know what you want, sign up for your 2015 benefits online at My Online Information or MOLI. If you are still debating on which health benefits to sign up for next year, go to our new employee benefits website and use Decision Direct, an interactive tool that gives you tips on which plan works best for you and your family.

When you access Decision Direct, you’ll be guided through a series of questions related to your health care preferences and how much you use and pay for health care during a year’s time. Once you’ve answered the questions, the tool will provide you with advice on which medical plan might be best for you.

Other tools and resources on the employee benefits website can help you estimate the cost of your prescription drugs and find a provider in your network. You also can compare the rates of the different health plans and learn about what each one has to offer.

If you still are unsure about which plan to sign up for or if you need assistance in the enrollment process, representatives from Human Resources will be offering their help from 11 a.m. to 3 p.m. Thursday, November 13, on The Auxiliary Bridge. On the last day of the enrollment period, Friday, November 14, the Total Rewards Main Phone Line at Ext. 4-2421 will be staffed from 7 a.m. to 7 p.m.

If you want to change plans or coverage levels, or if you want to participate in the Flexible Spending Account, you’ll need to elect your benefits during the enrollment period. If you don’t actively enroll during that time, your current medical, dental and other benefits will automatically carry over next year. Flexible Spending Account participation does not carry over from one year to the next, so you will need to reenroll.

111214Flushots640

If you are holding off on getting a flu shot because you got one last year and think it’s still protecting you, think again.

The flu vaccine is seasonal and is designed to protect against the main flu viruses that research suggests will cause the most illness during the upcoming flu season. Physician-in-Chief Dr. Mark W. Kline elaborates on why it’s important to get vaccinated against the flu each and every year.

“The flu is a virus that changes every year and the vaccine has to change with the virus,” Kline said. “We achieved a great protection rate last year, better than 90 percent here at Texas Children’s Hospital, but that doesn’t protect us this year. So, we are asking everyone to get a flu vaccine to protect themselves to protect their families and to protect their patients.”

According to the Centers for Disease Control and Prevention, a lot of research goes into the composition of the seasonal flu vaccine. More than 100 national influenza centers in more than 100 countries conduct year-round surveillance for influenza. This involves receiving and testing thousands of influenza virus samples from patients with suspected flu illness. The laboratories send representative viruses to five World Health Organization (WHO) Collaborating Centers for Reference and Research on Influenza.

In February of each year, WHO consults with experts from WHO Collaborating Centers, Essential Regulatory Laboratories, and other partners to review data generated by the worldwide network of influenza laboratories. Afterward, WHO makes recommendations for the composition of the seasonal influenza vaccine for the Northern Hemisphere.

The U.S. Vaccines and Related Biological Products Advisory Committee, which is a part of the U.S. Food and Drug Administration, considers the WHO recommendations and makes a final decision regarding the composition of seasonal flu vaccine for the United States.

Employee Health is administering free seasonal influenza vaccinations to all Texas Children’s employees, Baylor College of Medicine employees working in Texas Children’s facilities, Texas Children’s medical staff and volunteers. Leaders from Texas Children’s Pediatrics, Texas Children’s Health Centers and The Center for Women and Children will inform their staff about seasonal flu vaccination details.

Click here to view vaccination schedules for both Main and West Campuses. Employee Health strongly encourages you to get your vaccine at one of the times listed on the schedule. If you are unable to do so, please schedule an appointment to get the flu vaccine at the Employee Health Clinic.

And, remember, getting an annual flu shot is part of Texas Children’s P3 incentive plan, which is an important component of the total rewards you receive at Texas Children’s Hospital. As part of P3, we are amplifying unity and working together to get at least 90 percent of our staff vaccinated by Monday, December 1.